search
Back to results

Clinical Evaluation of FreeO2 (Version 4) in All Patients Receiving Oxygen (FreeO24G)

Primary Purpose

Respiratory Disease, Respiratory Failure, COPD Exacerbation

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
FreeO2
Sponsored by
Laval University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Respiratory Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > or = 18 years old
  • Patient receiving oxygen between 1 to 6 lpm for medical pathology
  • Admitted to a medical service for less than 72 hours (emergency room not included)

Exclusion Criteria:

  • Unreliable SpO2 signal
  • Emergency or intensive care hospitalization
  • Absence of NIV or intubation criteria at baseline
  • Sleep apnea not paired
  • Long-term Oxygen Therapy
  • Active delirium and cognitive impairment preventing informed consent

Sites / Locations

  • IUCPQ-ULRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Automated oxygen adjustment

Arm Description

All patient in this study have automatic oxygen titration and automatic oxygen weanning

Outcomes

Primary Outcome Measures

% of time in the set SpO2 target
Continuous SpO2 monitoring (1 data each second) will be recorded, the % of time within the SpO2 target±2% set by the physician will be considered (Time in the target±2/Total recording time)

Secondary Outcome Measures

Oxygenation data
the % of time with hyperoxia (SpO2 >= SpO2 target+4%), the % of time with severe hypoxemia (SpO2 <85%) the % of time without SpO2 signal, the % of time with oscillations of SpO2 values, comparison of Wired SpO2 vs Bluetooth SpO2, Daily variations of oxygen flows J1, J2 and J3 % Weaning> 50% relative baseline,% complete weaning of O2

Full Information

First Posted
April 12, 2017
Last Updated
February 25, 2019
Sponsor
Laval University
search

1. Study Identification

Unique Protocol Identification Number
NCT03119727
Brief Title
Clinical Evaluation of FreeO2 (Version 4) in All Patients Receiving Oxygen
Acronym
FreeO24G
Official Title
Clinical Evaluation of the Automatic Oxygen Adjustment by FreeO2 in a Medical Population in Hospital
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 30, 2017 (Actual)
Primary Completion Date
June 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of automatic titration of oxygen with a new version of FreeO2 (V4)
Detailed Description
In the previous studies, the investigators used many times automatic titration of oxygen on spontanous breathing patient (FreeO2 device) with a prototype develop in our lab in collaboration with Laval university. In this study, we want to evaluate the new version of the FreeO2 device (V4)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Disease, Respiratory Failure, COPD Exacerbation, Asthma, Pneumonia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Automated oxygen adjustment
Arm Type
Other
Arm Description
All patient in this study have automatic oxygen titration and automatic oxygen weanning
Intervention Type
Device
Intervention Name(s)
FreeO2
Intervention Description
All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
Primary Outcome Measure Information:
Title
% of time in the set SpO2 target
Description
Continuous SpO2 monitoring (1 data each second) will be recorded, the % of time within the SpO2 target±2% set by the physician will be considered (Time in the target±2/Total recording time)
Time Frame
During 3 days of hospitalization or until Oxygen weaning
Secondary Outcome Measure Information:
Title
Oxygenation data
Description
the % of time with hyperoxia (SpO2 >= SpO2 target+4%), the % of time with severe hypoxemia (SpO2 <85%) the % of time without SpO2 signal, the % of time with oscillations of SpO2 values, comparison of Wired SpO2 vs Bluetooth SpO2, Daily variations of oxygen flows J1, J2 and J3 % Weaning> 50% relative baseline,% complete weaning of O2
Time Frame
3 hospitalisations day or until Oxygen weaning

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > or = 18 years old Patient receiving oxygen between 1 to 6 lpm for medical pathology Admitted to a medical service for less than 72 hours (emergency room not included) Exclusion Criteria: Unreliable SpO2 signal Emergency or intensive care hospitalization Absence of NIV or intubation criteria at baseline Sleep apnea not paired Long-term Oxygen Therapy Active delirium and cognitive impairment preventing informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
François Lellouche
Phone
4186568711
Ext
4186568711
Email
francois.lellouche@criucpq.ulaval.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Pierre-alexandre Bouchard
Phone
4186568711
Ext
2712
Email
pierre-alexandre.bouchard@criucpq.ulaval.ca
Facility Information:
Facility Name
IUCPQ-UL
City
Quebec
ZIP/Postal Code
G1V4G5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre-alexandre Bouchard
Email
pierre-alexandre.bouchard@criucpq.ulaval.ca
First Name & Middle Initial & Last Name & Degree
François Lellouche

12. IPD Sharing Statement

Learn more about this trial

Clinical Evaluation of FreeO2 (Version 4) in All Patients Receiving Oxygen

We'll reach out to this number within 24 hrs